According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.
Medical
-
-
In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.
-
Can patients with bridge onychiasis and hypothyroidism have normal childbearing?
-
Medical
New Developments In Gastric Cancer Research: Keytruda In Combination With Chemotherapy Significantly Improves Survival In Patients With Advanced Disease!
Results from a pivotal phase 3 trial show that the PD-1 therapy Keytruda, in combination with chemotherapy, significantly improves survival in patients with advanced gastric cancer and has a favorable safety profile. Patients benefited regardless of their PD-L1 expression.
-
Medical
Pfizer's New Treatment Elranatamab Receives FDA Breakthrough Therapy Designation For Relapsed Or Refractory Multiple Myeloma
Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!
-
Medical
Japanese Scientists Find That Nmn Supplementation May Treat Retinal Dysfunction Caused By Cardiovascular Disease
New research by japanese scientists has found that
-
Medical
More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!
Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.
-
Dry eye after excimer surgery is a common problem. The main reason for the occurrence of dry eye after surgery is that during excimer surgery, the production of corneal flap and the cutting of matrix cut off the sensory nerve of part of the cornea, reducing the sensory and neurotrophic functions of the cornea, leading to the reduction of reflective tear secretion and the number of blinks, which leads to the reduction of the amount of tear secretion and the stability of the tear film. The study found that the corneal nerve after surgery can be restored to the preoperative level after 6-9 months of regeneration and repair. Therefore, dry eye may be obvious at the early stage after surgery, but it will gradually reduce with corneal repair until it returns to normal.
-
Medical
Innovative Therapy Zolbetuximab In Combination With Chemotherapy Significantly Improves Survival Of Gastric Cancer Patients!
New research confirms that the innovative treatment Zolbetuximab, in combination with chemotherapy, is highly effective in the treatment of gastric cancer, especially in advanced stages, and is expected to be a potential new treatment for patients with gastric cancer.
-
Many women suffering from hyperthyroidism hope to become pregnant or have a second child, but hyperthyroidism is a chronic disease, which often cannot be cured for a long time. Many people mistakenly believe that hyperthyroidism and pregnancy are absolutely "incompatible" and "irreconcilable", which undoubtedly brings a lot of gloom to patients' family life.